Karin E. Peterson

Dr. Karin E. Peterson

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Immunity
Verified
Journal Article
Closed access
UDUlf Dittmer
Ulf Dittmer
HHHong He
Hong He
RMRonald J. Messer
Ronald J. Messer
SSSimone Schimmer
Simone Schimmer
AOAnke R.M. Olbrich
Anke R.M. Olbrich
KHKim J. Hasenkrug
Kim J. Hasenkrug

17 July 2001 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
MIMichihiro Iwashiro
Michihiro Iwashiro
RMRonald J. Messer
Ronald J. Messer
KPKarin E. Peterson
Karin E. Peterson
ISIngunn M. Stromnes
Ingunn M. Stromnes
TSTomoharu Sugie
Tomoharu Sugie
KHKim J. Hasenkrug
Kim J. Hasenkrug
Normal levels of CD4+regulatory T cells are critical for the maintenance of immunological homeostasis and the prevention of autoimmune diseases. However, we now show that the expansion of CD4+regulatory T cells in response to a chronic viral infection can lead to immunosuppression. Mice persistently infected with Friend retrovirus develop approximately twice the normal percentage of splenic CD4+regulatory T cells and lose their ability to reject certain tumor transplants. The role of CD4+regulatory T cells was demonstrated by the transmission of immunosuppression to uninfected mice by adoptive transfers of CD4+T cells. CD4+T cells from chronically infected mice were also immunosuppressivein vitro, inhibiting the generation of cytolytic T lymphocytes in mixed lymphocyte cultures. Inhibition occurred at the level of blast-cell formation through a mechanism or mechanisms involving transforming growth factor-β and the cell surface molecule CTLA-4 (CD152). These results suggest a possible explanation for HIV- and human T cell leukemia virus-I-induced immunosuppression in the absence of T cell depletion.

1 April 2013 in Immunity
Verified
Journal Article
Closed access
PMPiyali Mukherjee
Piyali Mukherjee
TWTyson A. Woods
Tyson A. Woods
RMRoger A. Moore
Roger A. Moore
KPKarin E. Peterson
Karin E. Peterson

1 May 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Clayton WinklerClayton Winkler
Clayton Winkler
LMLara M. Myers
Lara M. Myers
TWTyson A Woods
Tyson A Woods
RMRonald J. Messer
Ronald J. Messer
ACAaron B. Carmody
Aaron B. Carmody
KPKarin E. Peterson
Karin E. Peterson
The recent association between Zika virus (ZIKV) and neurologic complications, including Guillain-Barré syndrome in adults and CNS abnormalities in fetuses, highlights the importance in understanding the immunological mechanisms controlling this emerging infection. Studies have indicated that ZIKV evades the human type I IFN response, suggesting a role for the adaptive immune response in resolving infection. However, the inability of ZIKV to antagonize the mouse IFN response renders the virus highly susceptible to circulating IFN in murine models. Thus, as we show in this article, although wild-type C57BL/6 mice mount cell-mediated and humoral adaptive immune responses to ZIKV, these responses were not required to prevent disease. However, when the type I IFN response of mice was suppressed, then the adaptive immune responses became critical. For example, when type I IFN signaling was blocked by Abs in Rag1−/− mice, the mice showed dramatic weight loss and ZIKV infection in the brain and testes. This phenotype was not observed in Ig-treated Rag1−/− mice or wild-type mice treated with anti–type I IFNR alone. Furthermore, we found that the CD8+ T cell responses of pregnant mice to ZIKV infection were diminished compared with nonpregnant mice. It is possible that diminished cell-mediated immunity during pregnancy could increase virus spread to the fetus. These results demonstrate an important role for the adaptive immune response in the control of ZIKV infection and imply that vaccination may prevent ZIKV-related disease, particularly when the type I IFN response is suppressed as it is in humans.

8 December 2009 in Glia
Verified
Journal Article
Closed access
PDF file
NBNiranjan B. Butchi
Niranjan B. Butchi
MDMin Du
Min Du
KPKarin E. Peterson
Karin E. Peterson

1 June 2008 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NBNiranjan B. Butchi
Niranjan B. Butchi
SPSusan Pourciau
Susan Pourciau
MDMin Du
Min Du
TMTim W. Morgan
Tim W. Morgan
KPKarin E. Peterson
Karin E. Peterson
Activation of astrocytes and microglia and the production of proinflammatory cytokines and chemokines are often associated with virus infection in the CNS as well as a number of neurological diseases of unknown etiology. These inflammatory responses may be initiated by recognition of pathogen-associated molecular patterns (PAMPs) that stimulate TLRs. TLR7 and TLR8 were identified as eliciting antiviral effects when stimulated by viral ssRNA. In the present study, we examined the potential of TLR7 and/or TLR8 agonists to induce glial activation and neuroinflammation in the CNS by intracerebroventricular inoculation of TLR7 and/or TLR8 agonists in newborn mice. The TLR7 agonist imiquimod induced astrocyte activation and up-regulation of proinflammatory cytokines and chemokines, including IFN-β, TNF, CCL2, and CXCL10. However, these responses were only of short duration when compared with responses induced by the TLR4 agonist LPS. Interestingly, some of the TLR7 and/or TLR8 agonists differed in their ability to activate glial cells as evidenced by their ability to induce cytokine and chemokine expression both in vivo and in vitro. Thus, TLR7 stimulation can induce neuroinflammatory responses in the brain, but individual TLR7 agonists may differ in their ability to stimulate cells of the CNS.